Endosense launches TOCCATA clinical study
Endosense, a medical technology company focused on enabling the broad adoption of catheter ablation for the treatment of cardiac rhythm disorders, has launched the TOCCATA clinical study to evaluate the safety of the TactiCath™ system with enrollment gaining momentum.
Endosense, a Geneva, Switzerland-based med-tech company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has raised $36 million in Series B funding.